Erectile dysfunction.
Erectile dysfunction (ED) is a highly prevalent and often undertreated condition. It may be a symptom of underlying, chronic illness and can have a negative impact on quality of life, psychosocial health, and relationships. The aging of the population, as well as the introduction of new treatment options, such as sildenafil, has led to increased public awareness of this disorder. New oral therapeutic agents are on the horizon. This article provides an overview of the physiology of erection, the pathophysiology of ED, and modern patient evaluation. Management options, including traditional therapeutic approaches as well as the new generation of oral agents, are also presented.
Shabsigh
Ridwan
R
Department of Urology, Columbia University College of Physicians and Surgeons, 161 Fort Washington Avenue, New York, New York 10032, USA. RS66@columbia.edu
Anastasiadis
Aristotelis G
AG
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D000527:Alprostadil / Q000502:physiology; D001058:Apomorphine / Q000627:therapeutic use; D001921:Brain / Q000503:physiopathology; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D007172:Erectile Dysfunction / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D008297:Male; D015917:Penile Prosthesis; D010413:Penis / Q000098:blood supply / Q000294:innervation; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D010727:Phosphoric Diester Hydrolases / Q000502:physiology; D010879:Piperazines / Q000627:therapeutic use; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones
D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human; D000527:Alprostadil; D001058:Apomorphine